Jeffrey E. Rubnitz

27.9k total citations · 1 hit paper
278 papers, 14.9k citations indexed

About

Jeffrey E. Rubnitz is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Molecular Biology. According to data from OpenAlex, Jeffrey E. Rubnitz has authored 278 papers receiving a total of 14.9k indexed citations (citations by other indexed papers that have themselves been cited), including 181 papers in Hematology, 158 papers in Public Health, Environmental and Occupational Health and 78 papers in Molecular Biology. Recurrent topics in Jeffrey E. Rubnitz's work include Acute Lymphoblastic Leukemia research (155 papers), Acute Myeloid Leukemia Research (147 papers) and Childhood Cancer Survivors' Quality of Life (64 papers). Jeffrey E. Rubnitz is often cited by papers focused on Acute Lymphoblastic Leukemia research (155 papers), Acute Myeloid Leukemia Research (147 papers) and Childhood Cancer Survivors' Quality of Life (64 papers). Jeffrey E. Rubnitz collaborates with scholars based in United States, Singapore and Australia. Jeffrey E. Rubnitz's co-authors include Ching‐Hon Pui, Raul C. Ribeiro, Susana C. Raimondi, Dario Campana, John T. Sandlund, Bassem I. Razzouk, Stanley Pounds, Hiroto Inaba, James R. Downing and Elaine Coustan‐Smith and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and JAMA.

In The Last Decade

Jeffrey E. Rubnitz

267 papers receiving 14.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia

2009 616 citations Elaine Coustan‐Smith, Charles G. Mullighan et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jeffrey E. Rubnitz United States	69	8.3k	8.0k	4.1k	4.1k	2.8k	278	14.9k
Stephen P. Hunger United States	68	12.3k 1.5×	7.4k 0.9×	4.2k 1.0×	7.3k 1.8×	4.0k 1.4×	374	18.2k
Bruce M. Camitta United States	60	6.9k 0.8×	6.8k 0.8×	1.8k 0.4×	4.2k 1.0×	2.4k 0.9×	215	12.5k
Martin Schrappe Germany	77	11.8k 1.4×	7.5k 0.9×	4.5k 1.1×	6.2k 1.5×	3.8k 1.3×	387	18.7k
Charles G. Mullighan United States	64	9.8k 1.2×	8.3k 1.0×	5.9k 1.4×	4.5k 1.1×	3.9k 1.4×	299	19.0k
André Baruchel France	55	4.3k 0.5×	4.3k 0.5×	3.0k 0.7×	2.4k 0.6×	1.6k 0.6×	333	9.7k
Gaston K. Rivera United States	53	6.9k 0.8×	4.6k 0.6×	2.2k 0.5×	3.9k 1.0×	2.1k 0.7×	166	11.2k
Selina M. Luger United States	47	3.2k 0.4×	5.4k 0.7×	2.9k 0.7×	1.2k 0.3×	2.9k 1.0×	304	9.7k
Bayard L. Powell United States	60	3.3k 0.4×	9.7k 1.2×	5.7k 1.4×	668 0.2×	2.8k 1.0×	260	14.2k
R.J. Arceci United States	62	2.2k 0.3×	3.1k 0.4×	5.1k 1.3×	1.3k 0.3×	3.5k 1.2×	390	12.5k
Arndt Borkhardt Germany	51	2.5k 0.3×	2.8k 0.4×	4.6k 1.1×	1.1k 0.3×	1.7k 0.6×	342	10.2k

Countries citing papers authored by Jeffrey E. Rubnitz

Since Specialization

Citations

This map shows the geographic impact of Jeffrey E. Rubnitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey E. Rubnitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey E. Rubnitz more than expected).

Fields of papers citing papers by Jeffrey E. Rubnitz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey E. Rubnitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey E. Rubnitz. The network helps show where Jeffrey E. Rubnitz may publish in the future.

Co-authorship network of co-authors of Jeffrey E. Rubnitz

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey E. Rubnitz. A scholar is included among the top collaborators of Jeffrey E. Rubnitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey E. Rubnitz. Jeffrey E. Rubnitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Badawi, Mohamed, Sathej Gopalakrishnan, Tammy L. Palenski, et al.. (2024). Dosing of Venetoclax in Pediatric Patients with Relapsed Acute Myeloid Leukemia: Analysis of Developmental Pharmacokinetics and Exposure-Response Relationships. Clinical Therapeutics. 46(10). 759–767.

Wu, Huiyun, Xueyuan Cao, Abdelrahman H. Elsayed, et al.. (2024). Pharmacogenomic Score Effectively Personalizes Treatment of Acute Myeloid Leukemia. Clinical Cancer Research. 30(19). 4388–4396. 1 indexed citations

Lu, Lu, Carrie R. Howell, Deo Kumar Srivastava, et al.. (2024). Severe Sepsis During Treatment for Childhood Leukemia and Sequelae Among Adult Survivors. JAMA Network Open. 7(3). e242727–e242727. 3 indexed citations

Lamba, Jatinder K., Huiyun Wu, Xueyuan Cao, et al.. (2023). Intensification of Therapy and Pharmacogenetic Personalization Mitigate Racial Disparities in Pediatric Acute Myeloid Leukemia Outcomes. Blood. 142(Supplement 1). 386–386. 1 indexed citations

Hoshitsuki, Keito, Yinmei Zhou, John Choi, et al.. (2023). Rituximab administration in pediatric patients with newly diagnosed acute lymphoblastic leukemia. Leukemia. 37(9). 1782–1791. 4 indexed citations

Christakopoulos, Georgios E., Jesse Smith, Clifford M. Takemoto, et al.. (2023). Clinical characteristics and outcomes of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis managed with different cytoreductive methods. Cancer. 129(12). 1873–1884. 3 indexed citations

Pfeiffer, Thomas, Ying Li, Seth E. Karol, et al.. (2022). Venetoclax-Based Combination Therapy As a Bridge to Allogeneic Hematopoietic Stem Cell Transplant in Children with Relapsed/Refractory AML. Transplantation and Cellular Therapy. 28(3). S120–S121. 2 indexed citations

Caldwell, Kenneth J., et al.. (2022). Relapsed acute myeloid leukemia in children and adolescents: current treatment options and future strategies. Leukemia. 36(8). 1951–1960. 14 indexed citations

Inaba, Hiroto, John C. Panetta, Stanley Pounds, et al.. (2019). Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory/Relapsed Leukemia or Solid Tumor Malignancies. Clinical Cancer Research. 25(24). 7320–7330. 15 indexed citations

10.

Bhojwani, Deepa, Noah D. Sabin, Deqing Pei, et al.. (2014). Methotrexate-Induced Neurotoxicity and Leukoencephalopathy in Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology. 32(9). 949–959. 242 indexed citations

11.

Baker, Sharyn D., Eric I. Zimmerman, Yong‐Dong Wang, et al.. (2013). Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia. Clinical Cancer Research. 19(20). 5758–5768. 75 indexed citations

12.

Alonzo, Todd A., Roland B. Walter, Robert B. Gerbing, et al.. (2013). Clinical Significance of CD33 Nonsynonymous Single-Nucleotide Polymorphisms in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab-Ozogamicin–Containing Chemotherapy. Clinical Cancer Research. 19(6). 1620–1627. 42 indexed citations

13.

Zimmerman, Eric I., Lie Li, David Finkelstein, et al.. (2012). Ontogeny and Sorafenib Metabolism. Clinical Cancer Research. 18(20). 5788–5795. 37 indexed citations

14.

Inaba, Hiroto, Elaine Coustan‐Smith, Xueyuan Cao, et al.. (2012). Comparative Analysis of Different Approaches to Measure Treatment Response in Acute Myeloid Leukemia. Journal of Clinical Oncology. 30(29). 3625–3632. 136 indexed citations

15.

Leung, Wing, Ching‐Hon Pui, Elaine Coustan‐Smith, et al.. (2012). Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood. 120(2). 468–472. 132 indexed citations

16.

Hu, Chaoxin, Cynthia S. Lancaster, Zhili Zuo, et al.. (2012). Inhibition of OCTN2-Mediated Transport of Carnitine by Etoposide. Molecular Cancer Therapeutics. 11(4). 921–929. 54 indexed citations

17.

Hu, Shuiying, Hongmei Niu, Shelley Orwick, et al.. (2008). Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia. Molecular Cancer Therapeutics. 7(5). 1110–1120. 31 indexed citations

18.

Rubnitz, Jeffrey E., David Wichlan, Meenakshi Devidas, et al.. (2008). Prospective Analysis of TEL Gene Rearrangements in Childhood Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. Journal of Clinical Oncology. 26(13). 2186–2191. 53 indexed citations

19.

Hijiya, Nobuko, John C. Panetta, Yinmei Zhou, et al.. (2006). Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia. Blood. 108(13). 3997–4002. 85 indexed citations

20.

Rubnitz, Jeffrey E., James R. Downing, & William M. Crist. (1998). Pathobiology and Clinical Significance of Molecular Genetic Findings in Childhood Tumors. Advances in Pediatrics. 45(1). 315–336. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact